[PDF][PDF] Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor–positive breast …

J Baselga, V Semiglazov, P van Dam… - Journal of Clinical …, 2009 - researchgate.net
J Baselga, V Semiglazov, P van Dam, A Manikhas, M Bellet, J Mayordomo, M Campone
Journal of Clinical Oncology, 2009researchgate.net
Purpose Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance
to endocrine therapy, and blockade of both pathways enhances antitumor activity in
preclinical models. This study explored whether sensitivity to letrozole was enhanced with
the oral mTOR inhibitor, everolimus (RAD001).
Purpose
Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activity in preclinical models. This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001).
researchgate.net